Florida SB 1768 names orthopedic conditions as one of only three categories within its authorized scope for non-FDA-approved stem cell therapy, alongside wound care and pain management. That places orthopedic surgeons and sports medicine physicians in Florida closer to the center of the state’s framework than any other specialty. For a physician already harvesting adipose tissue during procedures, that proximity raises a concrete operational question: what has to be documented, from harvest through storage, to keep a banking program compliant and to keep a patient’s future options open. What follows addresses harvest documentation, the split between banking consent and therapeutic-use consent, and the orthopedic trial pipeline that gives banking its forward-looking rationale.
TLDR: Florida SB 1768 authorizes non-FDA-approved stem cell therapy only for orthopedic conditions, wound care, and pain management, which positions Florida orthopedic physicians squarely within its scope. Compliant participation requires accredited and FDA-registered sourcing, a post-thaw viability report before each therapeutic use, the five statutory consent elements, and the posted and advertised notice. Harvest documentation (site, volume, method, transfer time, receiving facility, deviations) is the foundation of chain of custody required under both CGTP and the statute. Banking consent and therapeutic-use consent are separate documents for separate procedures and must not be combined. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. Stem cell therapies referenced here are investigational. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
The orthopedic physician’s position under SB 1768 is distinctive but not simple. Being inside the authorized scope at the state level does not resolve the federal questions that sit underneath, and the documentation burden that makes a banking program defensible is heavier than most practices anticipate. Treating both as planning problems before the first harvest, rather than paperwork to reconstruct later, is what separates a clean program from one that cannot prove what it did.
Why Orthopedic Physicians Are at the Center of SB 1768
SB 1768 limits authorized non-FDA-approved stem cell therapy to three condition categories: orthopedic conditions, wound care, and pain management. Orthopedic indications, joint disease, soft-tissue injury, tendon and ligament conditions, represent the largest and most actively studied clinical-trial pipeline among adipose-relevant musculoskeletal applications, which is why orthopedic and sports medicine physicians are the specialty most directly positioned to operate within the statute’s scope. The forward-looking version of the banking argument follows from that: an orthopedic surgeon who banks a patient’s adipose tissue today creates a documented, accessible autologous sample that the patient may be able to draw on as the evidence base develops, whether through an authorized pathway or a trial for which they later qualify. That is a statement about preserving optionality, not about guaranteeing a treatment, and it has to stay framed that way. The general case for adding banking to a practice is laid out in why physicians add adipose banking.
A Tension Orthopedic Physicians Must Understand First
Before the operational detail, one substantive point that orthopedic physicians specifically need to confront. SB 1768 authorizes orthopedic use at the state level, but the FDA’s July 2020 guidance treats musculoskeletal use of an adipose product, including for arthritis or tendon conditions, as non-homologous, which under federal law would require an IND. State authorization does not preempt the federal question. This is not a reason to avoid banking, which is a preservation step distinct from therapeutic administration, but it is a reason to work through the federal classification of any intended therapeutic use with counsel rather than treating the SB 1768 scope as the final word. The broader regulatory backdrop is covered in the FDA regulations overview for adipose tissue.
What SB 1768 Requires of the Orthopedic Provider
The statutory requirements apply to orthopedic use the same as any other authorized use, and the full checklist is detailed in the Florida SB 1768 compliance overview. In summary, the sourcing facility must be FDA-registered and accredited by one of the named bodies (the National Marrow Donor Program, the World Marrow Donor Association, the Association for the Advancement of Blood and Biotherapies, or the American Association of Tissue Banks). A post-thaw viability report must reach the physician before each therapeutic use, which at the point of care means the orthopedic provider should not proceed with administration until that report is in hand and reviewed. Informed consent must contain the five statutory elements: the FDA non-approval statement, the anticipated results, the available alternatives, the material risks, and the option to decline. And the statutory notice must be posted at the office entrance and included in advertising.
| Requirement | Orthopedic-specific application |
|---|---|
| Authorized scope | Orthopedic conditions, wound care, pain management only |
| Sourcing facility | FDA-registered and accredited (NMDP, WMDA, AABB, or AATB) |
| Post-thaw viability report | Received and reviewed before any joint or soft-tissue administration |
| Informed consent | Five statutory elements, on a dedicated therapeutic-use form |
| Posted notice | At office entrance, statutory format |
| Advertising notice | Same statutory notice in all ads |
Harvest Documentation for Orthopedic Providers
An orthopedic physician who harvests adipose tissue during a procedure, whether during an open or arthroscopic case or via a mini-lipoaspirate, is the origin point of the chain of custody, and the harvest record is its first link. At minimum, document the anatomical site of harvest, the volume harvested, the collection method and any instrumentation used, the time of harvest and of transfer to the processing container, the identity of the processing facility receiving the tissue, and any deviation from the standard collection protocol. This matters because chain of custody is required under both CGTP within 21 CFR Part 1271 and the sourcing logic of SB 1768, and a gap at the harvest step cannot be repaired downstream. A sample whose origin and handling cannot be documented is a sample whose regulatory status cannot be defended.
Consent: Banking vs. Therapeutic Use
Orthopedic physicians need to manage two distinct consent scenarios, and conflating them is a common and avoidable error. Banking consent covers the harvest and cryopreservation of adipose tissue for potential future use. It should disclose what banking is, what the tissue may later be used for, that any future therapeutic use is investigational and not guaranteed, and the conditions under which the tissue may be released. Therapeutic-use consent is a separate document obtained only if and when the physician later administers banked tissue under SB 1768, and it must meet all five statutory elements. These are two procedures with different risk profiles, so they take two forms. Do not combine them. The cross-state consent requirements that govern the therapeutic-use form are detailed in the guide to informed consent requirements in regenerative medicine.
The Orthopedic Trial Pipeline as Context
The forward-looking rationale for banking rests on an active research pipeline, which should be described as context rather than as a promise of access. Among the relevant programs, Mayo Clinic has run early-phase work on autologous adipose-derived cells for joint indications, and a Phase 3 program for knee osteoarthritis using an allogeneic umbilical-cord-blood-derived product (not an adipose therapy) cleared a US IND in early 2026, illustrating that musculoskeletal cell therapy is advancing through late-stage trials even though the specific cell sources differ. The honest framing for an orthopedic patient is narrow: these are investigational therapies at varying stages, banking does not guarantee enrollment in or access to any of them, but having banked autologous tissue on hand is a prerequisite for any autologous approach. The roundup of active adipose trials is covered separately, and physicians can learn to vet trials through the guide on finding legitimate clinical trials.
Harvest-to-Storage Documentation Checklist
- Patient identity confirmed at the time of harvest.
- Anatomical harvest site documented.
- Volume harvested documented.
- Collection method and instrumentation documented.
- Transfer time to the processing container documented.
- Processing facility name and contact confirmed.
- Chain-of-custody form initiated and signed at transfer.
- Banking consent signed and retained in the medical record.
- Therapeutic-use consent (separate form) obtained if and when applicable.
- Post-thaw viability report received and reviewed before any therapeutic use.
Frequently Asked Questions
Does SB 1768’s orthopedic authorization mean a Florida orthopedic surgeon can administer adipose cells for arthritis without federal concern?
No. SB 1768 authorizes orthopedic use at the state level, but the FDA’s July 2020 guidance treats musculoskeletal adipose use as non-homologous, which would require an IND federally. The state authorization does not resolve the federal question, and that overlap should be worked through with counsel.
Can one consent form cover both banking and later therapeutic use?
No. Banking and therapeutic use are separate procedures with different risk profiles. Banking consent covers harvest and cryopreservation; therapeutic-use consent must separately meet the five SB 1768 elements at the time of administration.
What is the single most overlooked harvest-documentation item?
The transfer step: the time of transfer and the identity of the receiving facility. Chain of custody depends on an unbroken record from harvest to storage, and a missing transfer entry is the gap that most often cannot be reconstructed later.
Key Takeaways
Florida orthopedic physicians sit inside SB 1768’s authorized scope, which makes a compliant banking program both more relevant and more demanding for them than for most specialties. The state authorization does not erase the federal reality that musculoskeletal adipose use is non-homologous and would require an IND, so the scope is a starting point for a conversation with counsel, not a clearance. Operationally, the work is documentation: a complete harvest record is the first link in a chain of custody that both CGTP and the statute require, and banking consent and therapeutic-use consent must stay as two separate forms for two separate procedures. The trial pipeline gives banking a forward-looking rationale, but the honest version is about optionality, a documented autologous sample that may matter later, never a promise of treatment. Banking remains a preservation decision separate from therapy, with no guarantee of future benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Florida orthopedic practices building a compliant harvest-to-storage workflow can contact Save My Fat to discuss how tissue preservation fits operationally.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
